Trial Profile

Effects of Empagliflozin on Liver Fat Content, Energy Metabolism and Body Composition in Patients With Type 2 Diabetes

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 07 Jun 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Empagliflozin (Primary)
Indications Type 2 diabetes mellitus
Focus Pharmacodynamics
Acronyms EmLiFa

Most Recent Events

20 Sep 2019 Results published in the Diabetes Care
11 Jun 2019 Primary endpoint (Change in liver fat content) has been met according to results presented at 79th Annual Scientific Sessions of the American Diabetes Association.
11 Jun 2019 Results (n=84) assessing effects empagliflozin on liver fat content were presented at the 79th Annual Scientific Sessions of the American Diabetes Association.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com